C07C 255/66
Having cyano groups and nitrogen atoms being part of hydrazine or hydrazone
Official title: having cyano groups and nitrogen atoms being part of hydrazine or hydrazone groups bound to the same carbon skeleton
C07C255/66 (Having cyano groups and nitrogen atoms being part of hydrazine or hydrazone) appears on 89 US grants and 55 published applications in this corpus.
Search patents in C07C- Granted patents
- 89
- Published applications
- 55
- Assignees
- 62
- Inventors
- 269
- Latest grant
- 31 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 3 | 0 |
| 1991 | 2 | 0 |
| 1992 | 0 | 0 |
| 1993 | 4 | 0 |
| 1994 | 2 | 0 |
| 1995 | 4 | 0 |
| 1996 | 4 | 0 |
| 1997 | 1 | 0 |
| 1998 | 10 | 0 |
| 1999 | 5 | 0 |
| 2000 | 3 | 0 |
| 2001 | 5 | 1 |
| 2002 | 3 | 5 |
| 2003 | 2 | 2 |
| 2004 | 1 | 4 |
| 2005 | 3 | 2 |
| 2006 | 4 | 3 |
| 2007 | 2 | 0 |
| 2008 | 2 | 4 |
| 2009 | 2 | 0 |
| 2010 | 0 | 3 |
| 2011 | 2 | 1 |
| 2012 | 1 | 2 |
| 2013 | 3 | 2 |
| 2014 | 2 | 6 |
| 2015 | 6 | 4 |
| 2016 | 3 | 3 |
| 2017 | 3 | 3 |
| 2018 | 0 | 2 |
| 2019 | 0 | 1 |
| 2020 | 1 | 1 |
| 2021 | 3 | 1 |
| 2022 | 0 | 3 |
| 2023 | 0 | 1 |
| 2024 | 1 | 1 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof31 Mar 2026US 12,590,071 B2Korea Institute of Science and Technology
- Myc-Max inhibitor compound therapeutics for cancer treatment, methods and uses associated therewith25 Jun 2024US 12,017,975 B2The University of British Columbia
- EPAC antagonists21 Sep 2021US 11,124,489 B2Board of Regents, The University of Texas System
- Compounds for the treatment of paramyxovirus viral infections25 May 2021US 11,014,935 B2Janssen BioPharma, Inc.
- Di(2-aryl hydrozonopropanal) arene derivatives20 Apr 2021US 10,981,872 B1King Abdulaziz University
- Covalent Inhibitors As Antiviral Agents3 Oct 2024US 2024/0327334 A1Enanta Pharmaceuticals, Inc.
- Myc-max inhibitor compound therapeutics for cancer treatment, methods and uses associated therewith4 May 2023US 2023/0134821 A1The University of British Columbia
- Novel hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof15 Dec 2022US 2022/0396553 A1Korea Institute of Science and Technology
- Compounds for the treatment of paramyxovirus viral infections15 Dec 2022US 2022/0396581 A1Janssen BioPharma, Inc.
- Myc-max inhibitor compound therapeutics for cancer treatment, methods and uses associated therewith14 Apr 2022US 2022/0112157 A1The University of British Columbia
Most cited
By later US patents
- Methods and compositions for inhibiting cell proliferative disorders109US 5,789,427 ASugen, Inc. · 1998
- FLK-1 is a receptor for vascular endothelial growth factor90US 5,851,999 AMax-Planck-Gesellschaft Zur FöRderung Der Wissenschaften E. V. · 1998
- Methods and compositions for inhibiting cell proliferative disorders85US 5,773,476 ASugen, Inc. · 1998
- Quinazoline compounds and compositions thereof for the treatment of disease84US 5,792,771 ASugen, Inc. · 1998
- Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis64US 5,712,395 ASugen, Inc. · 1998